Scinai Immunotherapeutics Cash Flow Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Net Income	-6.5	-5.8	-8.21	-1.26	-30.82	Upgrade
Depreciation & Amortization	0.51	0.56	0.47	0.69	0.46	Upgrade
Share-Based Compensation	1.14	1.6	2.76	2.67	1.04	Upgrade
Other Operating Activities	-4.54	-3.63	-2.45	-22.58	7.57	Upgrade
Operating Cash Flow	-9.38	-7.27	-7.43	-20.47	-21.75	Upgrade
Capital Expenditures	-0.64	-0.84	-0.14	-1.69	-2.1	Upgrade
Other Investing Activities	-	-	-	0.01	0.06	Upgrade
Investing Cash Flow	-0.64	-0.84	-0.14	-1.68	-2.03	Upgrade
Share Issuance / Repurchase	0.14	0.93	21.43	0.05	19.83	Upgrade
Debt Issued / Paid	0	0	0	-0.35	4.16	Upgrade
Other Financing Activities	0.95	5.84	-	4.17	0.05	Upgrade
Financing Cash Flow	1.09	6.78	21.43	3.87	24.05	Upgrade
Exchange Rate Effect	-0.27	-1.98	0.58	0.48	-1.23	Upgrade
Net Cash Flow	-9.21	-3.3	14.44	-17.79	-0.96	Upgrade
Free Cash Flow	-10.02	-8.1	-7.57	-22.16	-23.85	Upgrade
Free Cash Flow Per Share	-25.65	-42.97	-53.60	-199.97	-292.01	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).